#United States #St. Louis #CapyBio #Cell Identity #Engineered Cells

CapyBio Launches Innovative Cell Identity Services

CapyBio, a pioneering company in cell identity tools and services, has announced a significant advancement in cell engineering with the launch of three new commercial analysis services: Capybara™ Benchmarking Analysis, Capybara Advanced Analysis, and CellOracle™ Differentiation Optimization Analysis. These innovative services are designed to assist cell engineering teams in determining whether their engineered cells meet intended target states and identifying off-target states through comprehensive analysis.

As cell engineering continues to evolve, challenges such as incomplete maturation and lineage drift often leave researchers uncertain about the efficacy of their engineered cells. Traditional annotation methods frequently overlook these critical factors, leading to downstream failures in drug discovery, disease modeling, and cell therapy manufacturing. CapyBio aims to fill this gap with its expertise in cell identity.

The Capybara Benchmarking Analysis provides a comparative evaluation of engineered cells against established biological reference states. This enables teams to assess aspects such as target identity, maturation status, and the presence of any off-target populations that may be missed by standard techniques. Furthermore, the Capybara Advanced Analysis offers an in-depth characterization of cell identity and parameters related to heterogeneity and regulatory programs within these engineered populations.

Adding to the suite, CellOracle Differentiation Optimization Analysis employs sophisticated gene regulatory network modeling and in silico perturbation techniques to help teams identify the best strategies for enhancing cell identity. This service empowers researchers to make informed, data-driven decisions that could optimize their processes and improve outcomes.

Samantha Morris, PhD, Co-Founder of CapyBio, emphasizes the importance of these services: "After releasing our foundational publications, both academic institutions and biopharma companies reached out to us for assistance. They were generating vast amounts of single-cell data but lacked the appropriate tools and frameworks to extract meaningful insights. The demand underscored a crucial need in the industry, and we are thrilled to deliver these services to make advanced analysis accessible to all teams engaged in cell engineering."

CapyBio’s platform integrates findings from groundbreaking studies in single-cell genomics, enabling its application across various models, including organoids, cell therapy manufacturing, and regenerative medicine. In the realm of cell therapy manufacturing, precise profiling of cell identity can aid in a better comprehension of processes while allowing teams to enhance purity levels and yield outcomes.

In disease modeling, undetected off-target fates can yield misleading results during drug discovery, obscuring genuine biological signals. Additionally, CapyBio offers a portfolio of optional add-on services, like single-cell RNA sequencing—the foundational data for the Capybara platform. Customized options are available to cater to programs with specific experimental designs, facilitating tailored analytical approaches.

Guillermo Rivera, PhD, Chief Scientific Officer and Co-Founder, states: "For too long, researchers in cell engineering have relied on incomplete information for their protocol decisions. CapyBio transforms this decision-making process. Whether troubleshooting differentiation protocols, validating manufacturing processes for cell therapies, or deciphering unexpected behaviors in models, our services provide clarity, quantitative insights, and actionable pathways to move forward."

All CapyBio analysis packages and additional services are available immediately for researchers and biopharma teams eager to enhance their engineering processes. For further insights or to request a consultation, visit www.capybio.com or contact via email.

CapyBio, based in St. Louis, Missouri, is dedicated to empowering scientists through advanced benchmarking and diagnostic tools aimed at improving cell quality and research outcomes. With its expertise in single-cell biology, the company combines the Capybara framework with the CellOracle platform to provide solutions that enhance scientific and therapeutic progress.